Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
Second Tranche of BARDA Funding Supports Diagnostic Designed to Read Immune System and Rapidly Diagnose Acute Infection at Point of Care
BURLINGAME, Calif.--(BUSINESS WIRE)--Inflammatix, Inc., a pioneering molecular diagnostics company, announced today a contract extension of $7.4 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, to further develop its point-of-care test and system to diagnose infection by reading the immune system. The contract is part of a BARDA contract worth up to $72 million, if all options are exercised.
The new funding will support continued development and commercialization of Inflammatix’s sample-to-answer, point-of-care MyrnaTM test system, which is designed to read RNA using machine learning and produce results in under 30 minutes, as well as continued development of the ViraBac EZTM test (formerly known as HostDx Fever), which reads gene expression patterns in the immune system to identify whether a suspected infection is bacterial or viral, enabling physicians to quickly and accurately determine when to prescribe antibiotics. The test will use a fingerstick collection and capillary blood sample, and is designed for use in primary care, urgent care and other outpatient clinical settings.
One of the biggest threats to global health today is antibiotic resistance. Increasing and incorrect antibiotic use leads to antibiotic-resistant bacteria that become more difficult and costly to treat, and more deadly. Today, an estimated 30 percent of antibiotics are inappropriately prescribed to patients because their infections are not obviously bacterial or viral in origin.1 In addition, almost three million Americans each year become infected with bacteria that are resistant to antibiotics, with more than 35,000 dying as a direct result.2 New diagnostic methods that can help better direct antibiotics to only those patients that need them will be an important element in combating antibiotic resistance, ensuring that proven therapies can continue to fight disease and save lives.
“We are pleased to continue to partner with BARDA in the development of our ViraBac EZ test and Myrna instrument. Enabling physicians to make more informed decisions about which patients need antibiotics and which can avoid them has the potential to transform patient care at the point of care,” said Tim Sweeney, M.D., Ph.D., co-founder and chief executive officer of Inflammatix.
“In the physician’s office, current methods for diagnosing infections are slow, produce inconsistent results, and/or do not provide the information we need to confidently prescribe treatment,” said David Lin, MD, family medicine specialist with Sutter Health, Sacramento, California. “Having a test that allows us to quickly make more informed decisions about which patients are infected and could benefit from antibiotics would have a meaningful impact on patient care.”
Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company’s initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company’s sample-to-answer isothermal instrument platform in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, Calif.-based company is funded by Khosla Ventures, Northpond Ventures, the Stanford StartX Fund, Think.Health Ventures, and OSF Ventures. For more information, please visit www.inflammatix.com and follow the company on Twitter (@Inflammatix_Inc).
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00034.
- Hersh AL, King LM, Shapiro DJ, Hicks LA, Fleming-Dutra KE. Unnecessary antibiotic prescribing in US ambulatory care settings, 2010-2015. Clin Infect Dis. 2020; ciaa667, doi.org/10.1093/cid/ciaa667.
- Antibiotic/Antimicrobial Resistance. U.S. Centers for Disease Control and Prevention website. Updated July 20, 2020. Accessed October 7, 2020. https://www.cdc.gov/drugresistance/index.html.